APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
+23.63%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$4.28B
AUM Growth
+$4.28B
(-6.9%)
Cap. Flow
-$594M
Cap. Flow
% of AUM
-13.88%
Top 10 Holdings %
Top 10 Hldgs %
42.06%
Holding
115
New
18
Increased
32
Reduced
19
Closed
30
Top Buys
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$125M |
| 2 |
Universal Health Services
UHS
|
$116M |
| 3 |
Surgery Partners
SGRY
|
$79.2M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$65.2M |
| 5 |
Prothena Corp
PRTA
|
$59.4M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$289M |
| 2 |
Biogen
BIIB
|
$160M |
| 3 |
SPDR S&P Biotech ETF
XBI
|
$117M |
| 4 |
Humana
HUM
|
$103M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$98.4M |
Sector Composition
| 1 | Healthcare | 99.55% |
| 2 | Financials | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$43.6B
| $237M | 5.13% | 625,000 +133,200 | +27% | +$50.5M |
|
2
United Therapeutics
UTHR
$13.8B
| $218M | 4.73% | 785,500 -184,700 | -19% | -$51.4M |
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $213M | 4.61% | 1,780,000 -75,700 | -4% | -$9.04M |
|
4
Akero Therapeutics
AKRO
$3.74B
| $210M | 4.54% | 3,825,000 +703,000 | +23% | +$38.5M |
|
|
5
Prothena Corp
PRTA
$441M
| $178M | 3.85% | 2,953,000 +986,000 | +50% | +$59.4M |
|
6
Arvinas
ARVN
$568M
| $169M | 3.67% | 4,950,000 +606,500 | +14% | +$20.7M |
|
7
Boston Scientific
BSX
$156B
| $151M | 3.26% | 3,256,700 +718,100 | +28% | +$33.2M |
|
8
Syndax Pharmaceuticals
SNDX
$1.41B
| $149M | 3.23% | 5,861,000 +274,100 | +5% | +$6.98M |
|
9
Ultragenyx Pharmaceutical
RARE
$2.89B
| $139M | 3% | 2,990,000 +938,400 | +46% | +$43.5M |
|
10
Sarepta Therapeutics
SRPT
$1.78B
| $137M | 2.96% | 1,055,000 +106,800 | +11% | +$13.8M |
|
|
11
Madrigal Pharmaceuticals
MDGL
$9.76B
| $125M | 2.7% | +430,000 | New | +$125M |
|
|
12
Universal Health Services
UHS
$11.6B
| $116M | 2.52% | +825,600 | New | +$116M |
|
|
13
Jazz Pharmaceuticals
JAZZ
$7.75B
| $116M | 2.51% | 727,541 +409,241 | +129% | +$65.2M |
|
14
Zentalis Pharmaceuticals
ZNTL
$122M
| $104M | 2.25% | 5,150,000 +926,900 | +22% | +$18.7M |
|
15
Acadia Healthcare
ACHC
$2.12B
| $95.9M | 2.08% | 1,165,000 -224,200 | -16% | -$18.5M |
|
|
16
Surgery Partners
SGRY
$2.91B
| $86.7M | 1.88% | 3,112,000 +2,844,400 | +1,063% | +$79.2M |
|
17
DexCom
DXCM
$29.5B
| $85.7M | 1.86% | 756,800 +289,200 | +62% | +$32.7M |
|
18
AstraZeneca
AZN
$248B
| $81.4M | 1.76% | 1,200,000 +636,800 | +113% | +$43.2M |
|
|
19
Eli Lilly
LLY
$657B
| $79.4M | 1.72% | 217,000 -790,000 | -78% | -$289M |
|
20
Vaxcyte
PCVX
$4B
| $77.5M | 1.68% | 1,615,400 +986,700 | +157% | +$47.3M |
|
21
Avidity Biosciences
RNA
$5.99B
| $72.7M | 1.57% | 3,275,000 +675,000 | +26% | +$15M |
|
22
Natera
NTRA
$23.1B
| $72.3M | 1.57% | 1,798,900 +63,900 | +4% | +$2.57M |
|
23
IDEAYA Biosciences
IDYA
$2.15B
| $69.5M | 1.51% | 3,824,800 +109,400 | +3% | +$1.99M |
|
24
Immunocore
IMCR
$1.62B
| $65.9M | 1.43% | 1,154,000 -925,100 | -44% | -$52.8M |
|
25
Altimmune
ALT
$338M
| $65.6M | 1.42% | 3,990,000 +1,306,000 | +49% | +$21.5M |
|